SparingVision’s 3-pillar strategy
In this multi-part video series, SparingVision presents its corporate strategy and how we are developing new treatments across three core areas of expertise – what we call our “3 pillars”: gene and mutation-agnostic gene therapies, genome editing technologies, and in vivo reprogramming.
Watch below as our CEO, Stephane Boissel, provides an outline of the three pillars we are focused on here at SparingVision.
SparingVision’s 3-pillar strategy : gene therapy, the 1st pillar
Watch below as our CSO, Deniz Dalkara, discusses our first pillar: gene independent gene therapies.
SparingVision’s 3-pillar strategy : genome editing, the 2nd pillar
Watch below Caitlin Collin, Senior Scientist in Gene Editing, talk about our second pillar of exploration – genome editing – and our strategic collaboration with Intellia Therapeutics, Inc. to develop novel treatments utilizing their CRISPR-Cas9 technology.
Menu
Latest Tweets
Members of the SparingVision team will be presenting four posters at the European Society of Gene and Cell Therapy (@ESGCT) 2022 Congress in Edinburgh, 11-14 Oct. Find out more here: https://sparingvision.com/sparingvision-to-highlight-progress-of-its-lead-gene-independent-gene-therapy-programs-spvn06-and-spvn20-at-esgct-congress-2/
#ophthalmology #genomicmedicines
PARTNERS
